Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00969969
Other study ID # PTC-0031
Secondary ID
Status Completed
Phase Phase 3
First received September 1, 2009
Last updated November 10, 2016
Start date August 2009
Est. completion date July 2016

Study information

Verified date November 2016
Source Cartiva, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationCanada: Health CanadaUnited Kingdom: National Health Service
Study type Interventional

Clinical Trial Summary

This study will evaluate whether Cartiva is an effective treatment for individuals with osteoarthritis of the great toe.


Recruitment information / eligibility

Status Completed
Enrollment 236
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- = 18 years of age

- Osteoarthritis of the first metatarsophalangeal joint and is a candidate for arthrodesis

- Presence of good bone stock

- Capable of completing self-administered questionnaires

Exclusion Criteria:

- < 18 years of age

- Osteoarthritis of the first metatarsophalangeal joint, though is not a candidate for arthrodesis

- Active bacterial infection of the foot

- Additional ipsilateral limb (hip, knee, ankle, or foot) pathology that requires active treatment (surgery or brace)

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Arthrodesis
arthrodesis using screws and/or a plate
Cartiva
Cartiva Synthetic Cartilage Implant

Locations

Country Name City State
Canada University of Calgary Calgary Alberta
Canada University of Alberta Edmonton Alberta
Canada Horizon Health Network Fredericton New Brunswick
Canada Queen Elizabeth Science Centre Halifax Nova Scotia
Canada St. Michael's Hospital Toronto Ontario
Canada St. Paul's Hospital Vancouver British Columbia
United Kingdom Frimley Park Hospital - Surrey Foot and Ankle Clinic Frimley Camberley
United Kingdom Royal Surrey County Hospital Guildford Surrey
United Kingdom Northern General Hospital NHS Trusts - Sheffield Orthopaedics Sheffield South Yorkshire
United Kingdom Torbay Hospital South Devon Torquay
United Kingdom Royal National Orthopaedic Hospital - Stanmore Foot & Ankle Clinic Stanmore Middlesex
United Kingdom St. George's Hospital Tooting London

Sponsors (1)

Lead Sponsor Collaborator
Cartiva, Inc.

Countries where clinical trial is conducted

Canada,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary VAS, FAAM, Safety The individual components of the primary outcome measures will be Visual Analog Scale (VAS) Pain, Foot and Ankle Ability Measure (FAAM) Sports sub-scale score and absence of key safety issues. up to 2 years Yes
See also
  Status Clinical Trial Phase
Completed NCT02978573 - Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant in the Treatment of OA of the Great Toe Phase 3